BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20811665)

  • 1. CD98 expression is associated with the grade of malignancy in thymic epithelial tumors.
    Kaira K; Takahashi T; Abe M; Akamatsu H; Nakagawa K; Ohde Y; Okumura T; Murakami H; Tsuya A; Nakamura Y; Naito T; Kondo H; Nakajima T; Endo M; Yamamoto N
    Oncol Rep; 2010 Oct; 24(4):861-7. PubMed ID: 20811665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.
    Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Murakami H; Tsuya A; Nakamura Y; Naito T; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
    Lung Cancer; 2011 Dec; 74(3):419-25. PubMed ID: 21550686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.
    Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Serizawa M; Koh Y; Hanaoka H; Tominaga H; Oriuchi N; Kondo H; Nakajima T; Yamamoto N
    J Clin Oncol; 2010 Aug; 28(23):3746-53. PubMed ID: 20625125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.
    Kaira K; Murakami H; Serizawa M; Koh Y; Abe M; Ohde Y; Takahashi T; Kondo H; Nakajima T; Yamamoto N
    Virchows Arch; 2011 May; 458(5):615-20. PubMed ID: 21253760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors.
    Tomita M; Matsuzaki Y; Edagawa M; Maeda M; Shimizu T; Hara M; Onitsuka T
    J Thorac Cardiovasc Surg; 2002 Sep; 124(3):493-8. PubMed ID: 12202865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    J Surg Oncol; 2009 Jun; 99(7):433-8. PubMed ID: 19347882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of Epstein-Barr virus, cell proliferation and apoptosis in thymic tumors].
    Mai S; Xiong M; Zong Y; Li Z; Rao H
    Zhonghua Bing Li Xue Za Zhi; 1999 Apr; 28(2):89-92. PubMed ID: 11869513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma.
    Toyoda M; Kaira K; Shino M; Sakakura K; Takahashi K; Takayasu Y; Tominaga H; Oriuchi N; Nikkuni O; Suzuki M; Iijima M; Tsukamoto N; Nagamori S; Kanai Y; Oyama T; Chikamatsu K
    Head Neck; 2015 Nov; 37(11):1569-74. PubMed ID: 24913970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
    Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
    Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and immunohistochemical study of eight cases with thymic carcinoma.
    Tomita M; Matsuzaki Y; Edagawa M; Maeda M; Shimizu T; Hara M; Onitsuka T
    BMC Surg; 2002 May; 2():3. PubMed ID: 12049674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
    Kaira K; Serizawa M; Koh Y; Miura S; Kaira R; Abe M; Nakagawa K; Ohde Y; Okumura T; Naito T; Murakami H; Takahashi T; Kondo H; Nakajima T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Mar; 6(3):606-13. PubMed ID: 21289518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness.
    Chen FF; Yan JJ; Jin YT; Su IJ
    Hum Pathol; 1996 Oct; 27(10):1089-92. PubMed ID: 8892596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of homeobox B-13 correlates with angiogenesis, aberrant expression of EMT markers, aggressive characteristics and poor prognosis in pancreatic carcinoma.
    Zhai LL; Wu Y; Cai CY; Tang ZG
    Int J Clin Exp Pathol; 2015; 8(6):6919-27. PubMed ID: 26261579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis.
    Lococo F; Cesario A; Okami J; Cardillo G; Cavuto S; Tokunaga T; Apolone G; Margaritora S; Granone P
    Lung Cancer; 2013 Nov; 82(2):245-51. PubMed ID: 23992878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
    Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Tanaka S; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Cancer Sci; 2008 Dec; 99(12):2380-6. PubMed ID: 19018776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative activity and apoptosis in thymic epithelial neoplasms.
    Hiroshima K; Iyoda A; Toyozaki T; Supriatna Y; Shibuya K; Shimamura F; Haga Y; Yoshida S; Fujisawa T; Ohwada H
    Mod Pathol; 2002 Dec; 15(12):1326-32. PubMed ID: 12481014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localization of Mcl-1 and bcl-2 proteins in thymic epithelial tumours.
    Chen FF; Yan JJ; Chang KC; Lai WW; Chen RM; Jin YT
    Histopathology; 1996 Dec; 29(6):541-7. PubMed ID: 8971561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.
    Lattanzio R; La Sorda R; Facciolo F; Sioletic S; Lauriola L; Martucci R; Gallo E; Palmieri G; Evoli A; Alessandrini G; Ruco L; Rendina EA; Truini M; Chiarle R; Barreca A; Pich A; Ascani S; Remotti D; Tunesi G; Granone P; Ratto GB; Puma F; Pescarmona E; Piantelli M; Marino M; ; Carlini S; Cerasoli V; Corzani F; Melis E; Filippetti M; Canalini P; Palestro G; Lalle M; Ruffini E; Ceribelli A; Rinaldi M
    Lung Cancer; 2014 Aug; 85(2):191-6. PubMed ID: 24908332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.